Chemotherapy of Late Stage Breast Cancer Targeted Towards Cell Cycle Regulatory Components
Abstract
Our original goal was to target cell cycle regulatory components as a potential therapy for breast cancer. The target p16 is a tumor suppressor and a CDK inhibitor and is inactivated by gene methylation. The drug 5-aza-2'deoxycytidine (5-Aza-CdR), an inhibitor of DNA methylation, is targeted for reexpression of a repressed p16 in late stage breast cancer patients. Re-activation of the p16 gene in cells in which the gene is methylated will restore normal growth control and be efficacious in treatment of breast cancer. A mouse model for the action of the drug was developed and used to test the efficacy of the drug.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2002
- Accession Number
- ADA412793
Entities
People
- Robert A. Sclafani
Organizations
- University of Colorado Boulder